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Diphtheria toxin-like ADP-ribosyltransferases 1 and 5 (ARTD-1, ARTD-5) are poly ADP-
ribose enzymes (PARP) involved in non-homologous end-joining (NHEJ), which is the
major pathway of double-strand break (DSB) repair. In addition, ARTD-5, or Tankyrase
(TNKS), is a positive regulator of the WNT signaling implicated in the development and bio-
logical behavior of many neoplasms, such as Medulloblastoma (MB), in which radiotherapy
is an essential part of the treatment. The use of radiosensitizing agents may improve the
therapeutic index in MB patients by increasing the efficacy of radiotherapy, while reducing
toxicity to the neuroaxis. ARTD-5 seems to be a good molecular target for improving the cur-
rent treatment of MB. In this study, we used the small molecule XAV939, a potent ARTD-5
inhibitor with a slight affinity for ARTD-1, in different human MB cell lines. XAV939 inhibited
the WNT pathway and DNA-PKcs in our MB cells, with many biological consequences. The
co-administration of XAV939 and ionizing radiations (IR) inhibited MB cells proliferation and
clonogenic capacity, decreased their efficacy in repairing DNA damage, and increased IR-
induced cell mortality. In conclusion, our in vitro data show that XAV939 could be a very
promising small molecule in MB treatment, and these results lay the basis for further in vivo
studies with the aim of improving the current therapy available for MB patients.
Introduction
ARTDs, a superfamily of 17 proteins, play a crucial role in different cellular functions such as
DNA damage detection and repair, chromatin modification, mitotic apparatus formation, and
cell death by transferring ADP-ribose unit or units onto specific molecular targets (a post-
translational modification process referred to as “PARsylation”). Given this essential role in
DNAmechanism repair, several studies have been carried out to explore the therapeutic poten-
tial of ARTDs specific inhibitors. Thus, both in vitro and mice studies indicate the rationale to
combine ARTDs inhibitors with DNA damaging agents in many different tumor types. On Oc-
tober 24, 2014, AstraZeneca announced that the Committee for Medicinal Products for
Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opin-
ion recommending the marketing authorization of Lynparza (olaparib, an ARTD-1 and
ARTD-2 inhibitor) as monotherapy for the maintenance treatment of patients with relapsed
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BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal
cancer. [1–6].
The ARTD family member, ARTD-5, otherwise known as tankyrase (TNKS) has been
shown to be involved in a multitude of critical cellular processes; it consists of two isoforms
(TNKS1 and TNKS2), which share 85% amino acid sequence identity and have overlapping
functions [7–10].
TNKS1 regulates DNA repair via PARsylation mediated stabilization of DNA-dependent
Protein Kinase catalytic subunit (DNA-PKcs). The depletion of TNKS by siRNA-mediated
knockdown or its inhibition resulted in proteasome-mediated DNA-PKcs degradation. The
failure of the non-homologous end-joining (NHEJ) function on DNA damage mechanism,
the major pathway of DSB repair, is also evident. Correct DNA-PKcs activity is critical for the
NHEJ mechanism; hence, TNKS inhibition results in an increased sensitivity to DNA damage
agents [11–13].
Furthermore, it was shown that TNKS is a positive regulator of WNT signaling. TNKS-
mediated PARsylation of AXIN induces the degradation of AXIN, the concentration-limiting
component of the β-catenin destruction complex, and therefore, WNT pathway activation.
Thus, TNKS inhibition antagonizes the WNT pathway by promoting Axin stabilization [14].
Alterations of the WNT pathway often occur in Medulloblastoma (MB), a highly invasive
embryonal neuroepithelial tumor of the cerebellum (WHO, grade IV) [15–18]. By analyzing
gene-expression profiles, a recent study has proposed four subtypes of MB, each of which is
characterized by a distinct genetic profile, oncogenic pathway activation, and clinical outcomes.
Specifically, MB subgroup A is characterized by the WNT pathway, subgroup B is character-
ized by SHH signaling, and C and D are characterized by the expression of neuronal differenti-
ation genes [19,20].
Radiotherapy is particularly effective in MB treatment. Ionizing radiations (IR) induce dif-
ferent DNA damage typologies; the most critical lesions are DSBs [13]. Unfortunately, radio-
therapy is notorious for causing late-onset side effects, not only regarding the developing
cortex and deep brain structures, but also the posterior fossa; the risk is higher in younger pa-
tients [21–26].
The use of radiosensitizing agents, which target specific tumor cell characteristics, such as
their replication dependency and DNA repair defects, may improve the therapeutic index
by increasing the efficacy of radiotherapy, while reducing the toxicity and damage to the
developing brain.
This therapeutic strategy could be particularly useful in highly proliferative high-grade
childhood brain tumors such as MB, which arise in largely non-replicative normal tissues with
proficient DNA repair [27].
In this regard, TNKS seems to be an optimal molecular target to improve the currently
available therapy for MB, given its crucial role in the NHEJ pathway and, consequently, in DSB
repair. Moreover, as mentioned previously, TNKS depletion results in a WNT pathway inhibi-
tion that is strongly involved in MB development and biological behavior.
The small molecule XAV939 [14] is known to have a high affinity for TNKS proteins. In-
deed, the administration of this compound in several cell cultures results in TNKS PARP ac-
tivity inhibition and, therefore, a WNT pathway inhibition (mediated by Axin increasing)
and DNA-PKcs protein level reduction. XAV939 also binds to ARTD-1, but with approxi-
mately 10-fold lower affinity than to ARTD-5A/ARTD-5b [14,28,29]. Therefore, in this
study, we investigated the rationale for combining XAV939 administration with IR in MB
using an in vitromodel system. We used the small molecule XAV939 in two different human
MB cell lines, evaluating the radiosensitizing potentiality of this inhibition in this kind of
embryonal tumor.
XAV939 Effects in Medulloblastoma Cell Lines
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Materials and Methods
Cell culture
The study of the therapeutic potential of ARTD-1 and TNKS inhibition was conducted on two
different human MB cell lines: ONS-76 (derived from classic MB) and DAOY (desmoplastic
MB) [30–31]. (ONS-76 were kindly provided by Dr. Charles G. Eberhart, John Hopkins Uni-
versity, Baltimore, MD, with the agreement of Dr. Mike Bobola, University of Washington,
Seattle, WA). DAOY were purchased from American Type Culture Collection (ATCC;
Manassas, VA).
ONS-76 and DAOY cell lines were maintained, respectively, in RPMI 1640 (Roswell Park
Memorial Institute medium; Euroclone, Milan, IT), supplemented with 10% heat-inactivated
fetal bovine serum (FBS; Euroclone, Milan, IT), MEM (Minimum Essential Medium with ear-
le’s salts; Euroclone, Milan, IT), supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Euroclone, Milan, IT), and 1% sodium pyruvate (Eurobio, courtaboeuf Cedex, FR). Both
media were supplemented with 1% penicillin-streptomycin (Euroclone, Milan, IT), 1% 2 mM
L-glutamine (Euroclone, Milan, IT), and 1% non-essential amino acids (Euroclone, Milan, IT).
Cell cultures were maintained at 37°C in 5% CO2.
Protein extraction andWestern Blots
ONS-76 and DAOY nuclear and total proteins were extracted andWestern Blotting (WB) was
performed, as previously described [32]. The following primary antibodies were used at the re-
spective dilutions in blocking solution: rabbit polyclonal anti-β-catenin (H-102; Santa Cruz Bio-
technology, Santa Cruz, CA, USA) 1:1000; mouse monoclonal anti-DNA-PKcs 1:1000 (1C12;
Abcam, Cambridge, UK); goat polyclonal anti-Axin (R20; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) 1:500; polyclonal anti-β-actin (I-19; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) 1:1000; and mouse monoclonal anti-lamin B1 (ZL-b, ABcam, Cambridge, UK) 1:400.
Primary antibodies were detected with horseradish peroxidase (HRP)-labelled secondary anti-
bodies at the respective dilutions in blocking solution: anti-rabbit (GE Healthcare Europe
GmbH, Freiburg, DE) 1:1000; anti-mouse (GE Healthcare Europe GmbH; Freiburg, DE)
1:10000; and anti-goat (Santa Cruz Biotechnology, Santa Cruz, CA) 1:1000. Total DNA-PKcs,
β-actin, and Axin were detected on total protein extracts, while β-catenin and lamin B detection
was performed on nuclear extracts. β-actin and lamin B were used to check for total and nuclear
loading, respectively. The experiments were performed at least three times.
The electrophoretic separation for the detection of the high molecular weight DNA-PKcs
(460 kDa) and of the normalizer β-actin, was performed by using a 3.5%–12% gradient
SDS-PAGE: acrylamide 30% plus 0.8% bisacrylamide cross-linker in 1.5 mol/L Tris/HCl buffer,
pH 8.8, containing 0.05% sodium dodecyl sulfate (SDS). BioRad Protean II (BioRad, Hercules,
CA, USA) was used to cast two 16 cm gels, 1.5 mm thick. A peristaltic pump and a gradient
mixer (Sigma Aldrich Corporation, St. Louis, MO, USA) were also used to cast a resolving gel.
After the resolving gel had set (approximately 3 h), the stacking gel, consisting of 3% acrylam-
ide in 0.125 mol/L Tris/HCl, pH 6.8, and 0.1% SDS, was poured above the resolving gel and al-
lowed to polymerize around the comb that was inserted to form the sample lines (10 X 1 cm).
The samples were resuspended in Laemli Buffer (2% SDS, 10% glycerol, 5% 2-mercaptoetha-
nol, 0.002% bromphenol blue, 0.125 M Tris HCl, pH ~6.8), while the gels were setting, and
25 μl were applied to each lane. The gels were run at 21 mA overnight in a tank buffer contain-
ing 1.44% glycine, 0.3% Tris, and 0.1% SDS, pH 8.8, using a thermocirculator set at 0°C. The
next day, the gels were blotted with a limiting current of 1A for 5 h onto nitrocellulose using a
transfer buffer that contained 1.44% glycine, 0.3% Tris, pH 8.3, and 20% methanol. The BioRad
XAV939 Effects in Medulloblastoma Cell Lines
PLOS ONE | DOI:10.1371/journal.pone.0124149 April 2, 2015 3 / 14
blotting tank (BioRad, Hercules, CA, USA) contained plate electrodes and a supercooling coil.
The equipment was attached to a thermocirculator set at -13.5°C. Nitrocellulose membranes
were incubated with anti-DNA-PKcs and anti-β-actin antibody.
XAV939 and IR treatment
DAOY and ONS-76 cell lines were plated 24 h prior to treatment with 5 μM of XAV939 or
with equal DMSO volume, with radiations or with a co-administration of drug and radiations
(cells were treated with the small molecule and irradiated 8 h later).
XAV939 (Sigma-Aldrich Corporation, St. Louis, MO, USA) was solubilized in DMSO to a
stock concentration of 50 mM, which was diluted to a working concentration of 5 μM. Cultures
were maintained under these conditions for the duration of the designated time course. Con-
trols were exposed to DMSO alone.
Cells were irradiated with an Irradiateur Biologique 437C (CIS-BIO; Cedex, France) γ-ray
machine at a dose of 2 or 10 Gy and a dose rate of approximately 2 Gy/min.
Post treatments, the cells were analyzed at different time points. Cell growth, colony forma-
tion, mortality rate, and DNA repair efficacy were evaluated.
Cell growth analysis
ONS-76 and DAOYMB cell lines were plated at a density of 200,000 and 500,000 viable cells
per T25 flask, respectively, and treated as described above.
Cell number and viability were assessed using the Trypan blue reagent (Sigma-Aldrich Cor-
poration, St. Louis, MO, USA). The cells were collected by trypsin-EDTA treatment, pelleted
by gentle centrifugation, and resuspended in Trypan blue reagent to count viable cells using a
light microscope every day for 4 days after treatments. Multiple replicate flasks were assayed at
each time point in each experiment, and each sample was examined in three independent ex-
periments. At each time point, we report the mean cell number from all the scored flasks; error
bars display SE.
Cell mortality assay
In order to evaluate cell mortality, 200,000 cells were seeded in T25 culture flasks and collected
48, 72, and 96 h after treatments. Irradiated and control samples from each line were harvested
at corresponding time-points, trypsinized, and total cells were suspended 1:1 in Trypan Blue
solution. Dead and total cells from every sample were counted using a Neubauer chamber.
Multiple replicate flasks were assayed at every time point in each experiment, and each sample
was examined in three independent experiments. At each time point, we report the mean cell
number from all the scored flasks; error bars display SE.
In a second set of experiments, cells were treated with XAV939 at the indicated concentra-
tion and irradiated with a double 2 Gy dose. Mortality rate was then calculated.
In the histograms, cell mortality of the treated cells was normalized to DMSO control cells.
Clonogenic assay
ONS-76 and DAOY cell lines were seeded in low serum growth medium (1% FBS) at 300 and
500 cells/well, respectively, into 6-well plates. Sixteen hours after plating, cells were treated as
described above. Media were replenished every three days until colony formation was observed.
Colonies were stained with a solution of 2 mg/mL crystal violet in buffered formalin and ob-
served under a light microscope. Each assay was made at least three times and only colonies of
more than 50 cells were counted.
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The survival fraction at 2 Gy (SF2), determined as the ratio of the number of colonies
formed by irradiated cells to the number of colonies formed by non-irradiated cells, was
also calculated.
Neutral Comet Assay
In order to avoid high lyses temperatures, which could alter the assay reliability, we used the
protocol described by Olive and Banàth, with some modifications [33, 34]. MB cell lines treated
and untreated with XAV939 (5μM) were exposed to 10 Gy. Neutral Comet Assay was per-
formed 0, 16, and 24 h after radiation. Non-irradiated cells were used as controls. In short,
after treatments cells were resuspended in low melting agarose and immediately placed on mi-
croscopic slides (pre-coated with 0.5% normal melting agarose) under coverslips and, after aga-
rose solidification, they were lysed with specific basic buffer (2% sarkosyl, 0.5M Na2EDTA, pH
8.0, stored at 4°C) for at least 4 h at 37°C. After lysis, the slides were washed in electrophoresis
buffer (90 mM Tris buffer, 90 mM boric acid, 2 mM Na2EDTA, pH 8.5) and placed in a hori-
zontal gel electrophoresis chamber filled with fresh electrophoresis buffer. Electrophoresis was
conducted at 7 mA (0.6 V/cm) for 25 min and at a temperature not higher than 15°C. The
slides were then washed in distillated water, stained with a 20 μg/mL ethidium bromide solu-
tion for 20 min, and covered with cover glasses. The image analysis was performed on pictures
of 50 randomly selected comets per slide for each sample. Experiments were repeated at least
three times. Data show mean comet TM and SD.
Pictures were captured using a fluorescence microscope at 50X magnification. Free software,
CASP, was used to measure the Tail Moment (TM, % Tail DNA x length Tail) and quantify
DNA damage. Cells treated with hydrogen peroxide (at 10 μM for 15 min) were used as inner
controls to verify the specificity of the method used to recognize mainly DSBs [34].
Statistical analysis
Data are expressed as means ± SD. Statistical analyses were performed using Dunnett’s test
(WB densitometry analyses), one-way ANOVA, and Bonferroni’s post-test (clonogenic form-
ing assay, cell mortality) or two-way ANOVA test and Bonferroni’s post-test (growth curves
assay), and employed Prism 5.0 software (GraphPad Software, La Jolla, CA). Statistical signifi-
cance was set at p.05.
Results
XAV939 inhibits WNT pathway and DNA-PKcs in MB cell lines
XAV939 is known to induce WNT signaling inhibition by increasing Axin protein levels, there-
by promoting β-catenin degradation [14]. We found an effective increase in total Axin levels, 8
h after treatment with XAV939 (5 μM) and a decrease in β-catenin protein levels, both in total
and in nuclear extracts, at 16 h. Densitometry analyses revealed a 70% increase of total Axin
protein levels in DAOY cells and an 80% increase in ONS-76 cells, treated with XAV939
(5 μM) compared to DMSO treated control cells. Total β-catenin protein levels decreased by
about 30% in both cell lines compared to controls; whereas, in nuclear fraction, we found an
80% reduction of β-catenin levels (Fig 1A).
Moreover, since TNKS PARP activity is critical for DNA-PK catalytic subunit (DNA-PKcs)
stability [11], we tested whether XAV939 treatment affected DNA-PKcs protein levels in our
cell lines. Examination of DNA-PKcs levels after 8 h and 16 h of XAV939 treatment revealed a
significant protein abundance decrease compared to controls: we found a 50% reduction in
DAOY cells and a 40% reduction in ONS-76 cells (Fig 1B).
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The increase in Axin protein levels, followed by β-catenin reduction, and DNA-PKcs levels
inhibition confirmed the efficacy of XAV939 in affecting TNKS PARP activity on these MB
cell lines.
The co-administration of XAV939 and IR inhibits MB cell proliferation
and clonogenic capacity
XAV939 and IR effects on the viability of MB cell lines were assessed by comparing growth
curves. Cells were treated with 5 μM of XAV939 or with an equal DMSO volume, with
radiation (γ-ray, dose 2 Gy, dose rate ~ 2 Gy/min) or with a co-administration of drug
and radiation.
Fig 2A shows that the co-administration of XAV939 and IR strongly suppresses MB cell
proliferation in both cell lines. In DAOY cells, the greatest proliferation inhibition was
Fig 1. XAV939 inhibits TNKS PARP-activity in MB cell lines.WB analysis and densitometry of total and nuclear MB cells extracts after XAV939 treatment:
MB cell lines (DAOY, ONS-76) were treated with 5 μMXAV939 or with an equal volume of DMSO.A. Both cell lines showed an increase in total Axin protein
levels at 8 h after treatment (80% and 70% respectively in ONS-76 and DAOY compared to DMSO treated control, p<. 05), followed by a β-catenin decrease
in total (30%, p<. 05) and, in particular, in nuclear extracts, at 16 h after drug administration (80% reduction compared with control, p<. 001). B. XAV939
induced a DNA-PKcs protein level reduction of about 40% at 8 h and 16 h after treatment compared to non-treated control cells (p<. 05 in A, p<. 01 in B).
Densitometry data (mean ± s.e.) were normalized with β-actin (for total extracts) and lamin-b (for nuclear extracts) and are representative of the results
derived from three independent experiments.
doi:10.1371/journal.pone.0124149.g001
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Fig 2. XAV939 impairs the clonogenic and proliferative capacity and enhances MB cells radio-sensitivity. A.Growth curves assay. XAV939 (5 μM)
treated cells and IR (2 Gy) treated cells showed a similar growth rate with about 40% (DAOY) and 30% (ONS-76) reductions compared to DMSO control cells
(p<. 01). In both cell lines, the co-administration of XAV939 and IR induces a massive cell proliferation inhibition with a decrease of about 70% (p<. 001).
Each point represents the mean ± s.e. of three independent assays.B. Clonogenic forming assay. XAV939 alone (5 μM) inhibits a clone-forming ability in
both MB cell lines as well as IR treatment (2 Gy), with a clonogenic capability reduction of about 38% (p<. 01). The IR and drug co-administration induces a
drastic inhibition of clone-forming in both cell lines (70% reduction in DAOY cells and 81% in ONS-76 compared with control cells, p<. 001).
doi:10.1371/journal.pone.0124149.g002
XAV939 Effects in Medulloblastoma Cell Lines
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observed 72 h post IR in XAV939 pre-treated cells, with a 69.2% reduction in cell proliferation
compared to DMSO control cells (p<. 001, two-way ANOVA) and a 42.65% decrease in cell
number relative to DMSO irradiated cells (p<. 01, two-way ANOVA). In ONS-76 cells, we
found a massive inhibition in XAV939 and irradiated cells at 96 h after IR. At this time point,
we detected a 75% cell number reduction compared to DMSO control cells (p<. 001, two-way
ANOVA) and a 34% reduction compared with DMSO irradiated cells (p<. 001, two-way
ANOVA). Furthermore, our data showed that XAV939 alone is able to inhibit MB cell growth:
the greater proliferation decrease observed was at 72 h after drug administration (38.9% reduc-
tion in DAOY cells and 48.1% in ONS-76 cells, p<. 01, two-way ANOVA).
Analogous results were found for clonogenic capability. Both MB cell lines showed a signifi-
cant reduction (38%) of the colony formation after exposure to 5 μMXAV939 (p<. 01, one-
way ANOVA). Nevertheless, XAV939 and IR treated cells showed the greatest inhibition of
clonogenic formation compared to the other samples. In DAOY cells, we observed a 70.6%
clone number reduction in XAV939 and irradiated cells compared to control cells (p<. 001,
one-way ANOVA) and 55.6% relative to DMSO irradiated cells (p<. 01, one-way ANOVA);
whereas, in ONS-76 cells, reductions of 81% (p<. 001, one-way ANOVA) and 67.9% (p<. 05,
one-way ANOVA) were observed, respectively (Fig 2B).
By using clone formation data, we calculated SF2. We found that XAV939 reduced the SF2
from 0.66 to 0.29 in DAOY cells and from 0.58 to 0.19 in ONS-76 cells, indicating that PARP
activity inhibition halved the percentage of cells that survive radiation treatments. This con-
firms a concrete enhanced radiosensitivity in these MB cells.
XAV939 affects efficacy of DNA repair after IR
The critical cellular lesions in relation to cytotoxic effects generated by IR are DNA-DSBs
[12,13]. The DNA-PK pathway is one of the two most important pathways involved in
DNA-DSBs repair [1]. As TNKS is a positive regulator of this pathway by inducing DNA-PKcs
stability [10], we investigated whether XAV939 affects DNA repair efficacy after IR treatment.
On the other hand, ARTD-1 inhibition by XAV939 could also have a critical role in NHEJ
mechanisms [1].
The neutral comet assay was performed for this purpose, because of its ability to highlight
predominantly DSBs [33,34] (Fig 3). As a measure of DNA damage, we used TM, the most
common parameter, for analyzing the comet assay results. We utilized hydrogen peroxide (at
10 μM for 15 min) as a negative control, since it induces principally SSBs; whereas, DSBs are
considered very rare events [34].
First, we assessed the repair kinetics of IR-induced DSBs in DAOY and ONS-76 cells analyz-
ing TM at various time points after IR (0, 16, and 24 h, 10 Gy dose). Fig 3A and 3B show that
the highest TM value was observed, as expected, immediately after IR in both cell lines. At 16 h
after irradiation, we observed a decrease in TM, whereas 24 h after IR, we detected a TM value
similar to that of non-irradiated cells, suggesting that DNA damage was repaired. Moreover,
hydrogen peroxide did not induce a significant increase in TM compared to non-irradiated
cells, confirming the effectiveness of the method in highlighting mainly DSBs.
XAV939 and IR treated cells (both in DAOY and ONS-76 cells) showed an evident delay in
their capability to repair DNA damage caused by radiation. The repair kinetics of these cells
are slower than DMSO irradiated cells. Indeed, in XAV939 and IR treated cells at the same
time points, we consistently observed a much higher TM compared to IR treated cells. In
DAOY cells, 16 h after the radiations, we observed a TM comparable to the TM value found
immediately after IR and, at 24 h, XAV939 pre-treated cells showed a double TM value com-
pared to DMSO control cells. In ONS-76 cells, at 24 h after IR, we detected an almost double
XAV939 Effects in Medulloblastoma Cell Lines
PLOS ONE | DOI:10.1371/journal.pone.0124149 April 2, 2015 8 / 14
TM in XAV939 pre-treated cells in relation to DMSO control cells; whereas, it was higher than
30% at 16 h. These results suggest a poor efficacy of DNA damage repair in XAV939 and IR
treated cells compared to controls.
XAV939 increases IR-induced cell mortality
We evaluated, by trypan blue assay, whether cell proliferation inhibition and clonogenic forma-
tion reduction correlated with an increase in IR-induced cell mortality.
DAOY cells irradiated with a 2 Gy dose showed a 16.81%, 10.9%, and 9.3% mortality rate at
48, 72, and 96 h after radiation, respectively. Cells treated with 5 μM of XAV939 before IR
showed 23.5%, 17%, and 13% mortality rate with a 6.77%, 6.1%, and 3.7% increase (data not
shown). Normalizing data to controls, we observed, at 72 h and 96 h after radiation, about a
40% and a 45% increase in cell mortality in cells pre-treated with XAV939 compared to only
irradiated ones (Fig 4A): this difference was considered statistically significant (p<. 01 and
p<. 05, respectively, one-way ANOVA). ONS-76 cells, at the same time points, showed
Fig 3. XAV939 affects the DNA repair efficacy of MB cell lines. Neutral Comet Assay was performed on IR treated cells (10 Gy), with or without XAV939
administration, at different time points post radiations (0, 16, and 24 h). Histograms represent mean ± s.e. of TMmeasured in at least three independent
experiments for each treatment and time point. The greatest TM was observed immediately after IR treatment in both cell lines (A: DAOY, B: ONS-76).
XAV939 induces enhanced TM values at 16 h and 24 h after IR compared to DMSO irradiated cells indicating a minor DNA repair capacity. On the right of the
figure, a representative example of comets for each treatment obtained in DAOY (upper) and ONS-76 (down) cells.
doi:10.1371/journal.pone.0124149.g003
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a 10.61%, 9.11%, and 10.43% mortality rate after IR. In this cell line, XAV939 induced a slight
increase in IR-mediated cell mortality: 12.96%, 13.49%, and 13.23% with a difference of 2.35%,
4.38%, and 2.8%, respectively (data not shown). When we normalized data to controls, a statis-
tically significant increase in cell mortality between IR treated cells, XAV939, and irradiated
cells was observed at 72 h (52.8%, p<. 01 one-way ANOVA) and at 96 h (30%, p<. 05, one-
way ANOVA).
Fig 4. XAV939 improves cell mortality IR-induced. Histograms represent means ± s.e. of three independent experiments. Mortality rates of XAV939
treated cells, IR treated cells, XAV939, and IR treated cells are reported as relative percentages compared to DMSO control cells.A. Cell mortality after a 2
Gy dose administration: XAV939 alone does not induce a significant cell mortality increase in each time point considered. The greatest cell death was
observed in XAV939 and IR treated cells in both cell lines, with a statistically significant difference at 72 h and 96 h compared with IR treated cells (p<. 01
and p<. 05, respectively). B.Mortality rate in MB cell lines after two treatments with 2 Gy dose of IR. In both cell lines, cells treated with XAV939 and
irradiated, as described, showed a double mortality rate compared to DMSO irradiated cells (p<. 001).
doi:10.1371/journal.pone.0124149.g004
XAV939 Effects in Medulloblastoma Cell Lines
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Despite these results, we did not observe as strong an increase in cell mortality as expected.
Testing the hypothesis that a single 2 Gy dose was enough to affect proliferation and clono-
genic capability, but not enough to induce a massive increase in cell mortality, we irradiated
with a second 2 Gy dose. DAOY cells treated with XAV939 and γ -rays, with two doses of 2 Gy,
showed a 30.95% mortality rate compared to 16.17% of cells not treated with the small mole-
cule but only irradiated two times (p<. 001, one-way ANOVA). Similarly, in ONS-76 cells,
XAV939 administration induced an almost double mortality rate in cells irradiated, as de-
scribed, compared to cells treated with IR alone (17.75% and 9.8%, respectively, p<. 001, one-
way ANOVA). Fig 4B shows data normalized to non-irradiated controls: we report, in both cell
lines, about a 100% increase in mortality rate of XAV939 and irradiated cells compared to cells
treated with IR alone, as described. These data confirm an enhanced MB cell radiosensitivity
mediated by XAV939 administration. Finally, a statistically significant difference in mortality
rate was not detected between XAV939 treated cells and DMSO control cells, in both cell lines
and at all time points considered.
Discussion
In recent years, increasing interest has been focused on ARTD proteins because of their strong
involvement in the DNA repair mechanism. ARTD inhibitors were first developed as sensitiz-
ers to DNA-damaging chemotherapy or IR, and several highly potent and specific ones have
been used in clinical trials in cancer patients [2–4]. Olaparib (AZD2281) is an oral PARP-1
and PARP-2 inhibitor that has been commercialized by Astra Zeneca [6]. Nonetheless, Dre-
galla and co-workers focused on the therapeutic potential of ARTD-5 inhibition due to its cru-
cial role in the NHEJ pathway by using XAV939 small molecule [11]. On the other hand,
TNKS, but not PARP-1/PARP-2, is implicated in theWNT pathway by regulating Axin protein
levels [14]. Recent in vitro and in vivo studies showed that WNT pathway inhibition suppresses
MB growth, promoting cell cycle arrest followed by apoptosis [35,36].
In our in vitro study, XAV939-mediated ARTD-1 and ARTD-5 inhibition impairs the
growth and clonogenic capability of MB cell lines, but does not significantly increase cell mor-
tality, indicating the low toxicity of the drug. The most notable results observed on cell prolifer-
ation occurred following the co-administration of XAV939 and IR. In these experiments, we
treated cells with a 2 Gy dose that corresponded to the daily fraction of the total radiation dose
(36 Gy) usually used in standard MB therapy. At this low dose, we found a massive cell prolif-
eration inhibition in XAV939 pre-treated cells compared to DMSO irradiated cells. The assess-
ment of cell proliferation after irradiation is considered a valid assay for defining cell radiation
sensitivity because it provides information on the proliferative capacities of surviving cells after
radiation [37,38]. Our data suggest that XAV939 treatment induces an increase in radiosensi-
tivity of MB cells.
Comparable results were found when analyzing the clonogenic capacity of MB cell lines
after drug and IR treatments. Indeed, the same trend, obtained by growth curves analyses, was
observed using the clonogenic assay, the gold standard for the determination of radiation sensi-
tivity [37,38]. MB cells treated with a combination of XAV939 and γ-rays showed greater
clone-forming capability inhibition compared with cells treated with drug or IR alone. The re-
duction of SF2 in both MB cell lines confirmed greater radiosensitivity in XAV939 treated cells.
Given the role of ARTD-1 and TNKS in DNA damage repair and NHEJ, we hypothesized
that the observed radiosensitivity was caused by a minor efficacy in DSB mechanism repair. To
verify our idea, we used the comet assay, since it is a sensitive, rapid, and simple method for
displaying and quantifying cellular DNA damage [33,34]. Under neutral conditions, the assay
is able to detect predominately DSBs [32,37]. Nonetheless, the neutral version of the method
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needs adapting for individual cell types in order to achieve optimal sensitivity [34]. In our ex-
periments, we used the radiation dose of 10 Gy, which is considered an adequate dose for
studying DSB repair by the neutral comet assay [34]. In this case, our specific interest was to
confirm and quantify whether and how much XAV939 affects DNAmechanism repair in MB
cell lines.
The observed kinetic repair trend in control tests was in accordance with results of previous
studies [37–48]. Moreover, it has been shown that radiation-induced DSBs are rejoined no
later than 20 h in mammalian cell lines [46,48]. In our experiments, both MB cell lines showed,
24 h after IR, a TM comparable to non-irradiated cells, indicating a well-functioning DNA
repair mechanism.
Conversely, XAV939 and IR treated cells showed an evident delay in their capability to re-
store DNA. We focused on 16 h and 24 h time points because it was suggested that damage
measured after 4 h or more by treatments is an excellent index of the cell DNA injury restora-
tion ability [48].
Thus, the higher TM value and, therefore, conspicuous DNA damage in XAV939 and IR
treated cells at the time points considered, compared to the irradiated control cells, strongly
supports the hypothesis that MB cells after XAV939 administration, at the given dose, have
limited efficacy to repair DSBs. These data are in accordance with the cell growth and colony-
forming ability inhibition previously shown.
In conclusion, XAV939 affected the DNA injury restoration ability, ultimately implying an
improvement in the radiosensitivity of MB cells. XAV939-mediated PARP activity inhibition
impairs growth and clonogenic capability and increases the mortality rate of MB cell lines.
These results are most likely a consequence of TNKS PARP activity inhibition that leads to the
WNT pathway inhibition and to the DNA-PKcs instability, causing cell growth reduction and
radiosensibility. Since XAV939 also binds to ARTD-1 (also involved in DSB mechanism), but
with approximately 10-fold lower affinity than to ARTD-5A/ARTD-5b [14–16], we cannot ex-
clude that part of the shown radiosensitivity is due to this binding; further studies will shed
light on this.
Taken together, our in vitro data suggest XAV939 as a potential molecule for improving the
current therapy for MB. Our results lay the basis for further in vivo studies with the aim of de-
signing clinical trials combining XAV939 (or other drugs with similar or better affinity for
TNKS) with conventional radiotherapy. Potentially, this will lead to a more effective therapy,
with the possibility of reducing radiation doses and, at last, long term side effects.
To date, only in vitro studies on XAV939 have been performed; therefore, a study focusing
on systemic drug administration is needed to investigate the concrete clinical relevance of this
small molecule [49].
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